Healthcare
enGene Holdings Inc.(ENGN)
Live Price
Offline$1.72
-1.15% today
Window Change
-80.23%
Window
May 6, 2026 β Jun 24, 2026
- Market Cap
- $400.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -56.8%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 34 bars Β· May 6, 2026 β Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
enGene Holdings Inc. (ENGN) is a Healthcare stock with a market cap of $400.00M and listed on NASDAQ. The stock last traded around $1.72 and down 80.2% across the available one-year price window (May 6, 2026 β Jun 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -56.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -56.8%, free cash flow -104.7% with operating margin 0.0% and ROIC -40.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ENGN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 11, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -56.8%, with operating margin around 0.0%.
Benchmark Edge
ENGN vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ENGN
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ENGN Max Drawdown
-83.73%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ENGN and SPY.
Company Overview
enGene Holdings Inc.
NASDAQ Capital Market
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-GuΓ©rin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
- Leadership
- Ronald H. W. Cooper
- IPO Date
- Feb 1, 2022
- Employees
- 56
- Street Address
- 7171 Rue Frederick Banting
- Mailing
- Saint-Laurent, H4S 1Z9
- Region
- Saint-Laurent, CA
- Reporting Currency
- USD
- Investor Line
- 514 332 4888
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- β
- Price/Book
- 1.9
Growth
- Revenue
- 0.0%
- EPS
- -56.8%
- Free Cash Flow
- -104.7%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -55.8%
- ROIC
- -40.5%
Balance Sheet
- Debt/Equity
- 0.12
- Current Ratio
- 11.75
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.